The Bridge currently covers the following GLP-1 medications when prescribed for weight management: Wegovy (injection and pills) Zepbound (KwikPen only) Foundayo (pills) Important note on Zepbound: Only the Zepbound KwikPen is covered under the Bridge
The new label includes references to some of those postmarketing risks, including intestinal obstruction, [and] severe constipation including fecal impaction. Some patients who took Zepbound have filed lawsuits, accusing Eli Lilly of failing to properly warn them that Zepbound could increase their risk of severe gut problems, including bowel obstructions, pancreatitis, and gastroparesis
Licensed professionals under physician supervision.
Tirzepatide for Weight Loss Overview What is Tirzepatide and How is it Used for Chronic Weight Management
Medical Notice: GLP-1 receptor agonists are prescription medications with documented risks, side effects, contraindications, and eligibility requirements